Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR, O'Horo JC, Challener DW, Arndt L, Arndt RF, Clune CG, Culbertson TL, Hall ST, Heyliger A, Jackson TA, Kennedy BD, Larsen J, Hanson SN, Sweeten PW, Tulledge-Scheitel SM, Ganesh R.
Razonable RR, et al. Among authors: hall st.
Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23.
Mayo Clin Proc. 2022.
PMID: 36058578
Free PMC article.